|
End-of-day quote
Korea S.E.
2026-10-15
|
5-day change | 1st Jan Change | ||
| 4,220.00 KRW | -11.16% |
|
-22.85% | -38.66% |
| 09-20 | Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index | CI |
| 08-14 | Genome & Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Genome & Company
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,048,465 | 468,827 | 245,897 | 176,209 | 85,207 | 238,384 |
| Change | - | -55.28% | -47.55% | -28.34% | -51.64% | 179.77% |
| Enterprise Value (EV) 1 | 940,636 | 398,490 | 145,490 | 116,390 | 36,301 | 220,521 |
| Change | - | -57.64% | -63.49% | -20% | -68.81% | 507.48% |
| P/E | -24.9x | -13.7x | -4.74x | -3.72x | -4.17x | -33.5x |
| PBR | 9.49x | 5.26x | 2.55x | 2.98x | 1.8x | 2.36x |
| PEG | - | 0.7x | -0.1x | 0.43x | 0.1x | 0.5x |
| Capitalization / Revenue | 6,963x | 1,039x | 17.5x | 12.3x | 3.07x | 9.7x |
| EV / Revenue | 6,247x | 883x | 10.3x | 8.14x | 1.31x | 8.97x |
| EV / EBITDA | -37.4x | -11.9x | -3.03x | -2.49x | -2.17x | -9.77x |
| EV / EBIT | -35.3x | -11x | -2.53x | -2.11x | -1.5x | -7.54x |
| EV / FCF | -12.3x | -23.3x | -4.12x | -3.7x | -2.08x | -10.3x |
| FCF Yield | -8.16% | -4.3% | -24.3% | -27% | -48% | -9.74% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -1,596 | -1,269 | -1,842 | -1,681 | -660.2 | -205.3 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 150.6 | 451.2 | 14,085 | 14,296 | 27,745 | 24,587 |
| EBITDA 1 | -25,164 | -33,496 | -48,051 | -46,820 | -16,752 | -22,563 |
| EBIT 1 | -26,629 | -36,087 | -57,512 | -55,092 | -24,199 | -29,234 |
| Net income 1 | -30,732 | -34,117 | -51,838 | -47,466 | -20,112 | -6,428 |
| Net Debt 1 | -107,829 | -70,338 | -100,408 | -59,819 | -48,906 | -17,862 |
| Reference price 2 | 39,750.00 | 17,350.00 | 8,725.00 | 6,245.00 | 2,750.00 | 6,880.00 |
| Nbr of stocks (in thousands) | 26,376 | 27,022 | 28,183 | 28,216 | 30,984 | 34,649 |
| Announcement Date | 3/10/21 | 3/21/22 | 3/21/23 | 3/20/24 | 3/20/25 | 3/20/26 |
1KRW in Million2KRW
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 164M | |
| 20.07x | 7.14x | 14.31x | 1.48% | 68.98B | |
| 28.61x | 7.85x | 24.63x | 0.05% | 53.15B | |
| 35.29x | 6.26x | 18.73x | 0.92% | 50.83B | |
| 34.21x | 3.36x | 14.49x | -.--% | 44.61B | |
| -19.62x | 197.94x | -20.83x | -.--% | 40.57B | |
| 49.56x | 5.68x | 31.19x | -.--% | 42.53B | |
| 27.19x | 7.72x | 19.99x | 0.39% | 30.95B | |
| 29.37x | 6.23x | 16.17x | -.--% | 25.44B | |
| -13.66x | 5.14x | -6.23x | -.--% | 22.66B | |
| Average | 21.22x | 27.48x | 12.49x | 0.32% | 37.99B | |
| Weighted average by Cap. | 23.22x | 26.76x | 13.87x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A314130 Stock
- Valuation Genome & Company
Select your edition
All financial news and data tailored to specific country editions
